Two Seas Discloses 5.4% Stake (10.44M) in Arbutus Biopharma (ABUS)
Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025.
Rhea-AI Filing Summary
Two Seas Capital and affiliated reporting persons disclosed beneficial ownership of 10,443,317 common shares of Arbutus Biopharma (symbol: ABUS), representing 5.4% of the outstanding class as of June 30, 2025. The stake is held in two funds — 7,472,841 shares in the Two Seas Global (Master) Fund and 2,970,476 shares in the Two Seas LNP Opportunities (Master) Fund — and the reporting persons state they have sole voting and sole dispositive power over all reported shares. The filing includes a certification that the securities are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The disclosure references a total share count of 191,641,511 common shares used to calculate the percentage.
Positive
- Material disclosure: Reporting persons publicly disclose a 5.4% stake (10,443,317 shares) in Arbutus, meeting SEC reporting thresholds.
- Clear voting/dispositive authority: The filing states sole voting and sole dispositive power over all reported shares.
- Detailed allocation: Holdings are itemized between two funds: 7,472,841 and 2,970,476 shares, improving transparency.
- Certification of ordinary-course holdings: Item 10 affirms the securities are held in the ordinary course and not to change or influence control.
Negative
- None.
Insights
TL;DR Two Seas reports a material 5.4% position (10.44M shares) in Arbutus with sole voting/dispositive power, certified as ordinary-course holdings.
The filing shows a clear beneficial position of 10,443,317 shares, equal to 5.4% of Arbutus' 191,641,511 outstanding shares. Holdings are allocated between two funds (7,472,841 and 2,970,476 shares), and the reporting persons assert sole voting and dispositive authority. The statement under Item 10 that the securities are held in the ordinary course and not for control purposes frames this as a disclosure of material ownership rather than an attempt to influence governance. For investors, this is notable ownership-level information but contains no operational or strategic commitments.
TL;DR A >5% beneficial stake with sole voting/dispositive power is material for governance disclosure but is presented as non-control, ordinary-course ownership.
The report documents that Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi collectively hold 10,443,317 shares (5.4%), and explicitly state sole voting and dispositive power over those shares. Item 10 provides a certification that the shares were not acquired to change or influence control, which distinguishes this Schedule 13G-style disclosure from an activist 13D filing. The filing supplies precise holding amounts and the issuer share base used for the percentage calculation, allowing transparent assessment of ownership concentration.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Schedule 13G for Arbutus Biopharma (ABUS)?
What percentage of ABUS does the reported holding represent?
AI-generated analysis. How Rhea-AI works. Not financial advice.